Ticker LaunchFiled, not priced · OPTN
Option Therapeutics Inc.
Option Therapeutics Inc. publicly filed a registration statement on Form S-1 on Jan 26, 2026 for a proposed initial public offering on NYSE American under the ticker OPTN, and has not yet priced. Its latest amendment was filed on Mar 16, 2026. The filing shows a price range of $10.00–$12.00 per share. Underwriters named in the filing: ThinkEquity.
Option Therapeutics Inc. is a clinical-stage company developing drug therapies for liver disease. Its investigational candidate BIV201, a continuous infusion of terlipressin, has FDA Fast Track and Orphan Drug designations.
- Status
- Filed, not priced
- Ticker
- OPTN
- Exchange
- NYSE American
- Price range
- $10.00–$12.00
- First filed
- Jan 26, 2026
- Latest amendment
- Mar 16, 2026
- Underwriters
- ThinkEquity
- Sector
- Biotech & pharma
- Country / state
- NV
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
- Amendment history
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jan 26, 2026
- Latest amendment Mar 16, 2026
- All filings on EDGAR CIK 2070577
Other companies in the IPO pipeline
- V Capital Consulting Group LtdJan 28, 2026
- JOYBYTE HOLDINGS LtdJan 27, 2026
- SWOL Holdings Inc.Jan 27, 2026
- Starrygazey Inc.Jan 23, 2026
- Medikra Inc.Jan 20, 2026
- Palermo Technologies Inc.Jan 20, 2026